Figure 1

Overview of the study design. (a) Schematic diagram illustrating generation of cytarabine-resistant cell line variants (upper panel) and collection of bone marrow mononuclear cells before and after cytarabine treatment in AML patients (middle panel). Subsequently, molecular profiling, high-throughput drug testing and bioinformatics data integration from cytarabine-resistant cell line variants and patient samples were studied (lower panel) to clinically validate the results. (b, c) The sensitivity of MOLM-13 and SHI-1 parental and cytarabine-resistant variants to cytarabine was tested with cell viability assay after 72 h incubation with drug concentrations ranging from 1 to 10 000 nM. The bars represent mean ±s.d.